Due to a system-wide technology update, we are experiencing extremely high call volume. We appreciate your patience with our operators during this time. Thank you for choosing Fox Chase Cancer Center.
Fox Chase Cancer Center and Temple Health Welcome Urologist Dr. Justin Friedlander
PHILADELPHIA (July 20, 2022)—Fox Chase Cancer Center is pleased to announce the hiring of Justin Friedlander, MD, who has joined Temple Health and the Fox Chase Division of Urology and Urologic Oncology.
“Dr. Friedlander will be joining an experienced team of benign urologists which will work integrally with the urologic oncology team already well established at Fox Chase. The infusion of expertise that these physicians bring will further help us expand the range of advanced benign urologic treatment options available at Fox Chase and for Temple Health at large,” said Robert Uzzo, MD, MBA, FACS, President & CEO of Fox Chase Cancer Center.
Friedlander specializes in the treatment of kidney and ureteral stones and is one of the only physicians in the Philadelphia area to perform minimally-invasive percutaneous nephrolithotomy for large and complex kidney stones. He performs the most percutaneous kidney surgeries for kidney stone removal in the Delaware Valley and is highly experienced in treating rare and complex conditions, including cystinuria. He also one of a few physicians in the region who performs prostate enucleation for benign prostatic hyperplasia.
Friedlander received his medical degree from the Albert Einstein College of Medicine in New York before working as a urology resident at the Smith Institute for Urology at the Zucker School of Medicine at Hofstra/Northwell. He then completed an endourology fellowship at UT Southwestern Medical Center in Dallas.
Friedlander went on to become director of endourology and the Comprehensive Kidney Stone Center for Einstein Healthcare Network in Philadelphia. There, he held positions that included associate residency program director and chair of the clinical competency committee.
He has also served as an adjunct associate professor of urologic oncology for Fox Chase since 2014 and has been named one of Philadelphia magazine’s Top Doctors from 2019 to 2022.
“The addition of Dr. Friedlander to our urology practice represents an exciting step forward in our clinical offerings for patients with urologic conditions, further distinguishing us as leaders in the field,” said Uzzo.
Friedlander began work at Fox Chase on July 1 and will see patients at Fox Chase Cancer Center – Huntingdon Pike and Temple Urology at Suburban Hospital.
Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence five consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.
For more information, call 888-369-2427